SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) will hold a webcast and conference call
to discuss financial results and business highlights for the second
quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m.
The webcast (live and archived) and related slide presentation
can be accessed through
https://evofem.investorroom.com/2021Q2Results or directly at
https://edge.media-server.com/mmc/p/h6zpy9h5. Please connect to the
webcast at least 15 minutes prior to the start of the call to
download any software that may be required.
If participating by phone, please dial in approximately 15
minutes prior to the start of the call using (866) 503-5561 (U.S.
toll-free) or (253) 336-2965, and referring to conference ID
A telephone replay will be available for 24 hours after the
call at (855) 859-2056 (U.S.) or (404) 537-3406
(International), conference ID 9190716.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company launched its first FDA-approved commercial
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), in the United States in September 2020.
The Company is evaluating lead product candidate EVO100 for the
prevention of urogenital Chlamydia trachomatis and
Neisseria gonorrhoeae infection in women in the ongoing
Phase 3 clinical trial, 'EVOGUARD.' For more information,
please visit evofem.com.
Phexxi® is a registered trademark of Evofem
Investor Relations Contact
Evofem Biosciences, Inc.
Mobile: (917) 673-5775
View original content to download
SOURCE Evofem Biosciences, Inc.